Dermata Therapeutics Inc (DRMA) - Total Assets
Based on the latest financial reports, Dermata Therapeutics Inc (DRMA) holds total assets worth $5.07 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See DRMA net assets for net asset value and shareholders' equity analysis.
Dermata Therapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how Dermata Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Dermata Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Dermata Therapeutics Inc's total assets of $5.07 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 89.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Dermata Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Dermata Therapeutics Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dermata Therapeutics Inc's current assets represent 100.0% of total assets in 2024, an increase from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 89.5% of total assets in 2024, down from 96.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Dermata Therapeutics Inc Competitors by Total Assets
Key competitors of Dermata Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Dermata Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.56 | 3.44 | 0.16 |
| Quick Ratio | 4.56 | 3.44 | 0.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.96 Million | $4.74 Million | $-3.18 Million |
Dermata Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Dermata Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.33 |
| Latest Market Cap to Assets Ratio | 1.20 |
| Asset Growth Rate (YoY) | -55.7% |
| Total Assets | $3.53 Million |
| Market Capitalization | $4.25 Million USD |
Valuation Analysis
Above Book Valuation: The market values Dermata Therapeutics Inc's assets above their book value (1.20x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Dermata Therapeutics Inc's assets decreased by 55.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Dermata Therapeutics Inc (2019–2024)
The table below shows the annual total assets of Dermata Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.53 Million | -55.71% |
| 2023-12-31 | $7.98 Million | +14.89% |
| 2022-12-31 | $6.94 Million | -40.26% |
| 2021-12-31 | $11.62 Million | +1819.87% |
| 2020-12-31 | $605.45K | -70.69% |
| 2019-12-31 | $2.07 Million | -- |
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept… Read more